生脉注射液配合老年晚期胃癌化疗的临床观察

The clinic research of the effect of SHENG MAI injection combined with the chemotherapy in the elderly patients with advanced gastric cancer .

目的探讨生脉注射液在减轻老年晚期胃癌患者化疗中药物副反应和改善患者生存质量方面的作用。方法将符合研究标准59名患者随机分为治疗组33例和对照组26例,均接受ELF方案静脉化疗两周期,治疗组化疗期间接受生脉注射液治疗共4周。观察治疗前后两组患者近期疗效、生活质量评分、化疗期间患者胃肠道反应和骨髓功能抑制情况。结果治疗组KPS增加值≥10分者占75.8%,高于对照组(38.5%);两组均无IV度胃肠道反应,治疗组0～I度消化道反应者占87.9%,高于对照组(61.5%),治疗组II～III度消化道反应者占12.1%,低于对照组(34.6%);两组均无IV度骨髓功能抑制,治疗组0～I度骨髓功能抑制者占81.8%,高于对照组(53.8%),治疗组II～III度骨髓功能抑制者占18.2%,低于对照组(46.2%)。以上资料经统计学分析表明组间差异明显(P<0.05),有统计学意义。结论生脉注射液在减轻老年性晚期胃癌患者化疗药物副反应和改善患者生存质量方面作用显著。

Objective To study the therapeutic effects of SHENG MAI injection combined with the chemotherapy in the elderly patients who were suffered from the advanced gastric cancer. Methods All the 59 patients were treated with the ELF( Etoposide 100mg/m^2 CF 200mg/m^2 ,5-FU 500mg/m^2 iv d1~d5, 21days/cycle, 2cycles) regime, 33 patients in the treatment group were treated by SHENG MAI injection(50ml iv d1~14/cycle 2cycles) during the chemotherapy. Results Of the 33 patients enrolled in the treatment group, 75.8 percent patients had been improved the survival condition according to the KPS score (increment≥10), 87.9% patients had grade 0~I gastrointestinal effect, 81.8% had grade 0~I myelosuppression. Of the 26 patients in the control group, 38.5% patients had the KPS score(increment≥10), 61.5% patients had grade 0~I gastrointestinal effect, 53.8% patients had grade 0~I myelosuppression. The data above showed a remarkable difference between the two groups (P<0.05) . Conclusion SHENG MAI injection has an improvement in life quality, gastrointestinal effect and myelosuppression of the elderly patients during the chemotherapy.